0001104659-22-124593.txt : 20221205 0001104659-22-124593.hdr.sgml : 20221205 20221205164539 ACCESSION NUMBER: 0001104659-22-124593 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20221205 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221205 DATE AS OF CHANGE: 20221205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38128 FILM NUMBER: 221445587 BUSINESS ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 8-K 1 tm2231838d1_8k.htm FORM 8-K
0001651407 false --12-31 0001651407 2022-12-05 2022-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): December 5, 2022

 

Checkpoint Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38128   47-2568632

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)   (IRS Employer Identification No.)

 

95 Sawyer Road, Suite 110, Waltham, MA 02453

(Address of Principal Executive Offices)

 

(781) 652-4500

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share CKPT NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

Item 3.03.Material Modification to Rights of Security Holders.

 

On December 5, 2022, Checkpoint Therapeutics, Inc., (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware which (i) effected a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock par value $0.0001 (the “Common Stock”), and (ii) effected a reduction in the number of authorized shares of Common Stock from 135,000,000 to 50,000,000 (the “Authorized Share Reduction”).

 

The Reverse Stock Split will be effective on December 6, 2022. The Common Stock will be quoted on the Nasdaq Capital Market on a post-split basis at the open of business on December 6, 2022. The Company’s post-reverse split Common Stock has a new CUSIP number, 162828206, but the par value and all other terms of the Common Stock were not affected by the Reverse Stock Split.

 

The Company’s transfer agent, VStock Transfer, LLC, is acting as exchange agent for the Reverse Stock Split and will send instructions to stockholders of record regarding the exchange of certificates of Common Stock.

 

The foregoing description of the Amendment and the Reverse Stock Split set forth above does not purport to be complete and is qualified in its entirety by reference to the Amendment. A copy of the Amendment is being filed as Exhibit 3.1 to this Current report on Form 8-K and is incorporated herein by reference.

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously disclosed, on November 3, 2022 a majority of the voting power of the Company voted to approve an amendment (the “Plan Amendment”) to the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Incentive Plan”) to increase the number of shares of common stock available for issuance under the Incentive Plan, giving effect to the Reverse Stock Split, by 2,100,000 from 900,000 to 3,000,000.

 

A copy of the Plan Amendment is filed as Exhibit 10.1 to this report and is incorporated by reference in this Item 5.02.

 

Item 5.03Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The disclosures set forth in Item 3.03 of this Current Report on Form 8-K are incorporated into this Item 5.03 by reference.

 

Item 8.01Other Events.

 

On December 5, 2022, Checkpoint Therapeutics, Inc. issued a press release announcing the Reverse Stock Split. A copy of such press release is included as Exhibit 99.1 to this report.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are furnished herewith:

 

Exhibit No.   Description
3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc.
     
10.1   Amendment to Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan.
     
99.1   Press Release, dated December 5, 2022
     
104   Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 5, 2022 Checkpoint Therapeutics, Inc.
  (Registrant)
   
   
  By /s/ James F. Oliviero
    James F. Oliviero
    President and Chief Executive Officer

 

 

 

 EX-3.1 2 tm2231838d1_ex3-1.htm EXHIBIT 3.1

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

OF

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

CHECKPOINT THERAPEUTICS, INC.

 

Checkpoint Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows:

 

FIRST: That the Corporation’s original Certificate of Incorporation was filed on November 10, 2014.

 

SECOND: That the Board of Directors of the Corporation (the “Board”) duly adopted resolutions by written consent, after giving effect to the 10:1 reverse stock split, proposing and declaring advisable the amendment of the Amended and Restated Certificate of Incorporation of the Corporation, as follows:

 

RESOLVED, the first paragraph of ARTICLE IV of the Amended and Restated Certificate of Incorporation be replaced and amended in its entirety to read as follows:

 

1. Common Stock. The total number of shares of capital stock that the Corporation shall have the authority to issue is fifty million (50,000,000) shares of Common Stock, with $0.0001 par value, of which seven hundred thousand (700,000) shares are designated as Class A Common Stock (the “Class A Common Stock”). The powers, preferences and relative participating, optional and other special rights of the respective classes of the Corporation’s capital stock or the holders thereof and the qualifications, limitations and restrictions thereof are as follows:

 

THIRD: Upon the filing and effectiveness (the “Effective Time”) pursuant to the DGCL of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation, every ten (10) issued and outstanding shares or shares held by the Corporation as treasury stock of the Corporation’s common stock, par value $0.0001 per share, as of the date and time immediately preceding the Effective Time (the “Old Shares”), shall automatically be reclassified as and converted into one (1) validly issued, fully paid and non-assessable share of common stock of the Corporation (the “New Shares”) without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described below (the “Reverse Stock Split”). Further, every right, option and warrant to acquire Old Shares outstanding immediately prior to the Effective Time shall, as of the Effective Time and without any further action, automatically be reclassified into the right to acquire one (1) New Share based on the conversion ratio of shares of Old Shares to New Shares set forth in the preceding sentence, but otherwise upon the terms of such right, option or warrant (except that the exercise or purchase price of such right, option or warrant shall be proportionately adjusted).

 

No fractional shares shall be issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive cash (without interest or deduction) from the Corporation’s transfer agent in lieu of such fractional share interests upon the submission of a transmission letter by a stockholder holding the shares in book-entry form and, where shares are held in certificated form, upon the surrender of the stockholder’s Old Certificates (as defined below), in an amount equal to the product obtained by multiplying (a) the closing price per share of the Common Stock as reported on the Nasdaq Stock Market as of the date of the Effective Time, by (b) the fraction of one share owned by the stockholder.

 

FOURTH: Each holder of record of a certificate which immediately prior to the last trading day preceding the date of the Split Effective Time (the “Split Effective Date”) represents Old Shares (the “Old Certificates”) shall be entitled to receive upon surrender of such Old Certificates to the Corporation’s transfer agent for cancellation, a certificate (the “New Certificates”) representing the number of whole shares of common stock into and for which the shares formerly represented by such Old Certificates so surrendered are exchangeable. From and after the Effective Date, Old Certificates shall represent only the right to receive New Certificates pursuant to the provisions hereof.

 

 

 

 

FIFTH: That the stockholders of the Corporation approved and adopted such amendments by written consent in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.

 

SIXTH: That such amendment of the Amended and Restated Certificate of Incorporation of the Corporation was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

SEVENTH: This amendment shall be effective as of December 6, 2022.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment of the Amended and Restated Certificate of Incorporation to be signed by its President and Chief Executive Officer as of this 5th day of December, 2022.

 

CHECKPOINT THERAPEUTICS, INC.  
   
By: /s/ James F. Oliviero  
  James F. Oliviero, President and CEO  

 

[Signature Page to Certificate of Amendment of Certificate of Incorporation of Checkpoint Therapeutics, Inc.]

 

 

 

 EX-10.1 3 tm2231838d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

AMENDMENT TO THE

CHECKPOINT THERAPEUTICS, INC.

AMENDED AND RESTATED 2015 INCENTIVE PLAN

 

This Amendment to the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (the “Plan”), is hereby adopted, effective as of the date indicated below.

 

WITNESETH:

 

WHEREAS, Checkpoint Therapeutics, Inc. (the “Corporation”) maintains the Plan, and the Plan is currently in effect; and

 

WHEREAS, Section 16.1 of the Plan authorizes the Board or the Committee (as defined in the Plan) to amend the Plan, subject to certain limitations, including stockholder approval for certain amendments; and

 

WHEREAS, the Board has approved and authorized this Amendment to the Plan and has recommended that the stockholders of the Corporation approve this Amendment;

 

NOW, THEREFORE, BE IT RESOLVED, that the Plan is hereby amended as follows, effective as of December 6, 2022:

 

1. Section 5.1. of the Plan is hereby amended by increasing the share references in such section from 900,000 to 3,000,000, so that such section reads in its entirety as follows:

 

“5.1. NUMBER OF SHARES. Subject to adjustment as provided in Sections 5.2 and Section 15.1, the aggregate number of Shares reserved and available for issuance pursuant to Awards granted under the Plan shall be 3,000,000. The maximum number of Shares that may be issued upon exercise of Incentive Stock Options granted under the Plan shall be 3,000,000.”

 

2. Except as specifically set forth herein, the terms of the Plan shall be and remain unchanged, and the Plan as amended shall remain in full force and effect.

 

The foregoing is hereby acknowledged as being the Amendment to the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan, as adopted by the Board on November 3, 2022, and approved by the Corporation’s stockholders on November 3, 2022.

 

CHECKPOINT THERAPEUTICS, INC.  
   
By: /s/ James F. Oliviero  
  James F. Oliviero, President and CEO  

 

 

 

 EX-99.1 4 tm2231838d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Checkpoint Therapeutics Announces Reverse Stock Split

 

Waltham, MA – December 5, 2022 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock. Checkpoint expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on December 6, 2022.

 

The reverse stock split was approved on November 3, 2022 by Checkpoint’s Board of Directors and stockholders representing approximately 58% of the voting power of Checkpoint’s outstanding capital stock. The reverse stock split is intended to improve the marketability and liquidity of Checkpoint’s common stock and to remain in compliance with Nasdaq’s continued listing requirements.

 

Checkpoint’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “CKPT” following the reverse stock split, with a new CUSIP number of 162828206. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in Checkpoint’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued in connection with the reverse stock split and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced from approximately 93 million to approximately 9.3 million.

 

Checkpoint’s transfer agent, VStock Transfer, LLC, is also acting as the exchange and paying agent for the reverse stock split. VStock Transfer, LLC will provide instructions to stockholders regarding the process for exchanging physical share certificates. Checkpoint does not expect that stockholders holding their shares in book-entry form or through a bank, broker or other nominee need to take any action in connection with the reverse stock split. Beneficial holders are encouraged to contact their bank, broker or other nominee with any procedural questions. Additional information concerning the reverse stock split can be found in Checkpoint’s definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on November 14, 2022.

 

About Checkpoint Therapeutics

 

Checkpoint is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”) intended to support one or more applications for marketing approval. Following positive topline and interim results in metastatic and locally advanced cSCC, respectively, Checkpoint intends to submit a Biologics License Application for these indications later this year. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements relating to the reverse stock split improving the marketability and liquidity of our common stock and to remain in compliance with Nasdaq’s continued listing requirements, statements relating to the potential differentiation of cosibelimab, including a potentially favorable safety profile as compared to the currently available anti-PD-1 therapies, the two-fold mechanism of action of cosibelimab translating into potential enhanced efficacy, projections of publication and regulatory submission timelines, and our planned price disruptive strategy generating substantial market share for cosibelimab in the U.S. Factors that could cause our actual results to differ materially include the following: our ability to successfully deliver the complete dataset from the clinical trial and complete a BLA submission on schedule as planned; the risk that topline and interim data remains subject to audit and verification procedures that may result in the final data being materially different from the topline or interim data we previously published; the risk that safety issues or trends will be observed in the clinical trial when the full safety dataset is available and analyzed; the risk that a positive primary endpoint does not translate to all, or any, secondary endpoints being met; risks that regulatory authorities will not accept an application for approval of cosibelimab based on data from the Phase 1 clinical trial; the risk that the clinical results from the Phase 1 clinical trial will not support regulatory approval of cosibelimab to treat cSCC or, if approved, that cosibelimab will not be commercially successful; risks related to our chemistry, manufacturing and controls and contract manufacturing relationships; risks related to our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks related to our need for substantial additional funds; other uncertainties inherent in research and development; our dependence on third-party suppliers; government regulation; patent and intellectual property matters; competition; and our ability to achieve the milestones we project, including the risk that the evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in our other filings with the U.S. Securities and Exchange Commission.

 

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. This press release and prior releases are available at www.checkpointtx.com.

 

 

 

 

Company Contact:

Jaclyn Jaffe

Checkpoint Therapeutics, Inc.

(781) 652-4500

ir@checkpointtx.com

 

Investor Relations Contact:

Ashley R. Robinson

Managing Director, LifeSci Advisors, LLC

(617) 430-7577

arr@lifesciadvisors.com

 

Media Relations Contact:

Katie Kennedy

Gregory FCA

610-731-1045

Checkpoint@gregoryfca.com

 

 

 

 EX-101.SCH 5 ckpt-20221205.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 ckpt-20221205_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 ckpt-20221205_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 tm2231838d1_ex99-1img01.jpg GRAPHIC begin 644 tm2231838d1_ex99-1img01.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Dec. 05, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 05, 2022
Current Fiscal Year End Date --12-31
Entity File Number 001-38128
Entity Registrant Name Checkpoint Therapeutics, Inc.
Entity Central Index Key 0001651407
Entity Tax Identification Number 47-2568632
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 95 Sawyer Road
Entity Address, Address Line Two Suite 110
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code 781
Local Phone Number 652-4500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CKPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 10 tm2231838d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001651407 2022-12-05 2022-12-05 iso4217:USD shares iso4217:USD shares 0001651407 false --12-31 8-K 2022-12-05 Checkpoint Therapeutics, Inc. DE 001-38128 47-2568632 95 Sawyer Road Suite 110 Waltham MA 02453 781 652-4500 false false false false Common Stock, par value $0.0001 per share CKPT NASDAQ true true EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +*%A54'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "RA8553[3C!N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NDTW#E&7"]-.("$Q"<0M2KPMHFFBQ*C=VY.6K1."!^ 8^\_G MSY);'83V$9^C#QC)8KH;7=^"V@6XES]$SMW@%V28[)+:AB&GQY=YW<+V MB52O,?]*5M YX(9=)[\V#]O]CDE><5[4O*C6>UZ+U5HTJ_?)]8??3=AY8P_V M'QM?!64+O^Y"?@%02P,$% @ LH6%59E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "RA855T;^VN:P$ !I$@ & 'AL+W=O9292*% M7]9*)]S"J=ZT3:8%#XN@)&XSW^^W$RY3;S(JKLWU9*1R&\M4S#4Q>9)PO?LD M8K4=>]1[O_ D-Y%U%]J34<8W8B'LMVRNX:Q=JH0R$:F1*B5:K,?>E%Y_8@,7 M4-SQNQ1; M'[^K?RY>'EYFQ8V8J?A9AC8:>T./A&+-\]@^J>VOXO!"/:<7J-@4GV2[O[?G M>R3(C57)(1@($IGNO_G;(1%' 5UV(H = EC!O7]007G#+9^,M-H2[>X&-7=0 MO&H1#7 R=5596 V_2HBSDYEZ%7K4MB#E+K2#0]BG?1@[$78C@DOB]RX(\QG[ M;W@;"$H,5F*P0J^#89"_IBMC-13J[SJBO4*W7L%U[[7)>"#&'K2G$?I5>),? MOJ-]_V>$KU/R=3#UR8T*'#UCT"T2TANJC*% C"@N)SS#=U M%'C\FL=&(!R]DJ-W7C+F0DL5DMLT)-!\M7EI4')M5/114R/U2[8^JCC+M2XR M)$W 8_*'X!KEP]5:+8>U&8(UYE%(GC)E'1#(Q*:9R*W,C 7Y"X-+A'. MJY+SZAS.&=140SWOTE"\D7NQJR/%E7Q(7[]'N_X P:)^Y9O^.6!+_D;N0J"3 M:QGP8J(Y7=X&R>Z@Q7K]8;^##01ZY.ST'$(HA-*9T@704 M4JO"VKHWJ-_<8I"5[U/4MM\AIV$(I@UM M% \QRLK]*>[?*.5RJVHI<:FV:2T<+O?, M8QOQ!$.K)@N*>_Q'M+(!YUJ]RC2H+S&N^3#%T*JY@N+V_A%MKHP%D_E39J=' M!:[HLVZO@[%5\P7%S;ZHX!06VJ=1<('!$)NW:#514-SAOR@WDVO)X]HE+*[2R%-Y/\/=>:Y%*X#T"!A?^W4K+!W!$;^NU_7U:]!K)#M: MZ./N_#^R.V-R(&L$Q&4; 2NO9[@Q+Z6%-9I:$\I^7/U$%B+(H=]J%QP-2JX_ M83VPL"IXN2 9K$1?>9P+\KU_Z18C)(/W-1'7*':AZ[_%KMDI>J[ M#Q>8W<^7&$GE^ QWY_>4D=NW(.+I1IQ<6S8(/4X7-]/?,*;*ZME95G^;"+UQ M6?H%%&SD+"3C:7UQ<4&K<[1NE=&SAG\&;H-"A.11P2A5Y)L1Q$8"06*Q!Q[\<0'WT?E]C?V)55NPE MK)2U*BD.(\%AX+H;X/>U4O;]Q&U/E+M+DW\!4$L#!!0 ( +*%A56?H!OP ML0( .(, - >&PO9KEMWDOSA MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!> M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V& M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V; MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \ M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^ M8* \^>Q\ETWLJ.?]74_P$4$L#!!0 M ( +*%A567BKL

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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://checkpointtx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2231838d1_8k.htm ckpt-20221205.xsd ckpt-20221205_lab.xml ckpt-20221205_pre.xml tm2231838d1_ex10-1.htm tm2231838d1_ex3-1.htm tm2231838d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2231838d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2231838d1_8k.htm" ] }, "labelLink": { "local": [ "ckpt-20221205_lab.xml" ] }, "presentationLink": { "local": [ "ckpt-20221205_pre.xml" ] }, "schema": { "local": [ "ckpt-20221205.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CKPT", "nsuri": "http://checkpointtx.com/20221205", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231838d1_8k.htm", "contextRef": "From2022-12-05to2022-12-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://checkpointtx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231838d1_8k.htm", "contextRef": "From2022-12-05to2022-12-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkpointtx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-124593-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-124593-xbrl.zip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end